• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比较血液透析和血液透析滤过对终末期肾病患者左心室肥厚影响的系统评价和荟萃分析。

Comparison of the effects of hemodialysis and hemodiafiltration on left ventricular hypertrophy in end-stage renal disease patients: A systematic review and meta-analysis.

机构信息

Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY.

Fondazione Policlinico Agostino Gemelli IRCCS, University Hospital, Università Cattolica del Sacro Cuore, Rome.

出版信息

Semin Dial. 2020 Mar;33(2):120-126. doi: 10.1111/sdi.12864. Epub 2020 Mar 11.

DOI:10.1111/sdi.12864
PMID:32159258
Abstract

Whether hemodiafiltration (HDF) is better than conventional hemodialysis (HD) in improving left ventricular hypertrophy (LVH), defined as reduction of the left ventricular mass index (LVMi) and increasing the ejection fraction (EF), is unclear. A systematic literature search was performed. Primary outcome was the mean difference between pre- and post-procedural LVMi. Secondary outcome was the mean difference in EF. Seven studies with a total of 845 patients were included. The pooled mean difference between pre-and post-procedural LVMi was -8.0 g/m (95% confidence interval [CI] -13.1, -2.8). On subgroup analysis, the mean differences between pre- and post-procedural LVMi for HD and HDF were -6.7 g/m (95% CI -14.5, 1.1) and -9.3 g/m (95% CI -16.3, -2.3), respectively (P for subgroups = .62). Pooled mean difference between pre- and post-procedural EF was 2.4% (95% CI -1.8, 6.5). On subgroup analysis, the mean differences between pre- and post-procedural EF for HD and HDF were 3.6% (95% CI -2.7, 9.8) and 2.0% (95% CI 2.9, 6.8), respectively (P for subgroups = .68). On meta-regression, age (Beta -0.35 ± 0.05, P < .001) and longer dialysis duration (Beta -0.12 ± 0.02, P < .001) were associated with lower mean difference between pre-and post-procedural EF. No significant effects on changes in LVMi and EF were observed with HDF compared with conventional HD.

摘要

在改善左心室肥厚(LVH)方面,血液透析滤过(HDF)是否优于常规血液透析(HD),定义为左心室质量指数(LVMi)降低和射血分数(EF)增加,目前尚不清楚。进行了系统的文献检索。主要结局是 LVMi 术前和术后的平均差值。次要结局是 EF 的平均差值。纳入了 7 项研究,共 845 例患者。LVMi 术前和术后的平均差值为-8.0 g/m(95%置信区间 [CI] -13.1,-2.8)。亚组分析显示,HD 和 HDF 治疗前后 LVMi 的平均差值分别为-6.7 g/m(95% CI -14.5,1.1)和-9.3 g/m(95% CI -16.3,-2.3)(P 亚组=.62)。EF 术前和术后的平均差值为 2.4%(95% CI -1.8,6.5)。亚组分析显示,HD 和 HDF 治疗前后 EF 的平均差值分别为 3.6%(95% CI -2.7,9.8)和 2.0%(95% CI 2.9,6.8)(P 亚组=.68)。元回归分析显示,年龄(Beta -0.35 ± 0.05,P <.001)和透析时间较长(Beta -0.12 ± 0.02,P <.001)与 EF 术前和术后的平均差值较低相关。与常规 HD 相比,HDF 对 LVMi 和 EF 的变化没有显著影响。

相似文献

1
Comparison of the effects of hemodialysis and hemodiafiltration on left ventricular hypertrophy in end-stage renal disease patients: A systematic review and meta-analysis.比较血液透析和血液透析滤过对终末期肾病患者左心室肥厚影响的系统评价和荟萃分析。
Semin Dial. 2020 Mar;33(2):120-126. doi: 10.1111/sdi.12864. Epub 2020 Mar 11.
2
A randomized trial of hemodiafiltration and change in cardiovascular parameters.血液透析滤过与心血管参数变化的随机试验。
Clin J Am Soc Nephrol. 2014 Mar;9(3):520-6. doi: 10.2215/CJN.07140713. Epub 2014 Jan 9.
3
Effects of high efficiency post-dilution on-line hemodiafiltration or conventional hemodialysis on residual renal function and left ventricular hypertrophy.高通量在线血液透析滤过或常规血液透析对残余肾功能和左心室肥厚的影响。
Int Urol Nephrol. 2013 Oct;45(5):1389-96. doi: 10.1007/s11255-012-0336-4. Epub 2012 Dec 7.
4
Left Ventricular Mass Index in End-Stage Renal Disease Patients during Hemodialysis and Continuous Ambulatory Peritoneal Dialysis.终末期肾病血液透析和持续不卧床腹膜透析患者的左心室质量指数。
Int J Clin Pract. 2023 Dec 11;2023:8816478. doi: 10.1155/2023/8816478. eCollection 2023.
5
Cardiovascular protective effects of on-line hemodiafiltration: comparison with conventional hemodialysis.在线血液透析滤过的心血管保护作用:与传统血液透析的比较
Ther Apher Dial. 2012 Apr;16(2):181-8. doi: 10.1111/j.1744-9987.2011.01042.x. Epub 2012 Feb 2.
6
Effect of frequent or extended hemodialysis on cardiovascular parameters: a meta-analysis.频繁或延长血液透析对心血管参数的影响:荟萃分析。
Am J Kidney Dis. 2012 May;59(5):689-99. doi: 10.1053/j.ajkd.2011.12.020. Epub 2012 Feb 25.
7
Levocarnitine Improves Cardiac Function in Hemodialysis Patients With Left Ventricular Hypertrophy: A Randomized Controlled Trial.左卡尼汀改善血液透析伴左心室肥厚患者的心脏功能:一项随机对照试验。
Am J Kidney Dis. 2016 Feb;67(2):260-70. doi: 10.1053/j.ajkd.2015.09.010. Epub 2015 Oct 23.
8
The effect of on-line hemodiafiltration on improving the cardiovascular function parameters in children on regular dialysis.在线血液透析滤过对改善规律透析儿童心血管功能参数的影响。
Saudi J Kidney Dis Transpl. 2015 Jan;26(1):39-46. doi: 10.4103/1319-2442.148731.
9
Fibroblast growth factor-23 (FGF-23) / soluble Klotho protein (sKlotho) / sclerostin glycoprotein ratio disturbance is a novel risk factor for cardiovascular complications in ESRD patients receiving treatment with regular hemodialysis or hemodiafiltration.成纤维细胞生长因子-23(FGF-23)/可溶性klotho蛋白(sKlotho)/骨硬化蛋白糖蛋白比值紊乱是接受常规血液透析或血液滤过治疗的终末期肾病(ESRD)患者发生心血管并发症的一个新的危险因素。
Ter Arkh. 2018 Jun 20;90(6):48-54. doi: 10.26442/terarkh201890648-54.
10
Correlation between hypervolemia, left ventricular hypertrophy and fibroblast growth factor 23 in hemodialysis patients.血液透析患者中高血容量、左心室肥厚与成纤维细胞生长因子23之间的相关性。
Ren Fail. 2015 Jul;37(6):951-6. doi: 10.3109/0886022X.2015.1052945. Epub 2015 Jun 1.

引用本文的文献

1
Effect of hemodiafiltration and hemodialysis on mortality of patients with end-stage kidney disease: a meta-analysis.血液透析滤过和血液透析对终末期肾病患者死亡率的影响:一项荟萃分析。
BMC Nephrol. 2024 Oct 22;25(1):372. doi: 10.1186/s12882-024-03810-9.
2
Echocardiographic Indices in Patients with End-Stage Renal Disease and Their Association with Hemodialysis-to-Hemodiafiltration Transfer: A Prospective Observational Study.终末期肾病患者的超声心动图指标及其与血液透析向血液透析滤过转换的关系:一项前瞻性观察研究。
Medicina (Kaunas). 2024 Sep 20;60(9):1537. doi: 10.3390/medicina60091537.
3
Unveiling the Clinical Benefits of High-Volume Hemodiafiltration: Optimizing the Removal of Medium-Weight Uremic Toxins and Beyond.
揭示高通量血液滤过的临床益处:优化中分子量尿毒症毒素及其他物质的清除
Toxins (Basel). 2023 Aug 29;15(9):531. doi: 10.3390/toxins15090531.
4
Why should we focus on high-volume hemodiafiltration?我们为什么要关注高通量血液透析滤过?
Kidney Res Clin Pract. 2022 Nov;41(6):670-681. doi: 10.23876/j.krcp.21.268. Epub 2022 Feb 22.